{"id":"NCT00087529","sponsor":"Genentech, Inc.","briefTitle":"A Study to Evaluate the Safety and Efficacy of Rituximab in Adults With Primary Progressive Multiple Sclerosis","officialTitle":"A Phase II/III, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Rituximab in Adults With Primary Progressive Multiple Sclerosis","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2004-06","primaryCompletion":"2007-10","completion":null,"firstPosted":"2004-07-13","resultsPosted":"2015-09-09","lastUpdate":"2015-09-09"},"enrollment":439,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Multiple Sclerosis"],"interventions":[{"type":"DRUG","name":"placebo","otherNames":[]},{"type":"DRUG","name":"rituximab","otherNames":[]}],"arms":[{"label":"1","type":"EXPERIMENTAL"},{"label":"2","type":"PLACEBO_COMPARATOR"}],"summary":"This is a Phase II/III, randomized, double-blind, parallel group, placebo controlled, multicenter study to evaluate the safety and efficacy of rituximab in adults with PPMS. The study will enroll approximately 435 subjects at up to 60 sites in the United States and Canada.","primaryOutcome":{"measure":"Time to Confirmed Disease Progression (CDP)","timeFrame":"96 weeks (from Screening to Week 96, and at least 12 weeks after initial progression)","effectByArm":[{"arm":"Placebo","deltaMin":null,"sd":null},{"arm":"Rituximab","deltaMin":null,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.1442"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":30},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["40258203","36163349","23027880","19847908"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":20,"n":147},"commonTop":["Fatigue","Muscular weakness","Fall","Urinary tract infection","Headache"]}}